MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Retained Earnings 2011-2026 | EGRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 75.9 M | 84.5 M | 72.5 M | 58.2 M | 26.3 M | -25.7 M | -107 M | -104 M | -102 M | -95.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 112 M | -107 M | -527 K |
Quarterly Retained Earnings Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 117 M | 112 M | 103 M | 110 M | 120 M | 75.9 M | 82.1 M | 87.7 M | 84.1 M | 84.5 M | 84.5 M | 84.5 M | 84.5 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | -25.7 M | -25.7 M | -25.7 M | -25.7 M | -107 M | -107 M | -107 M | -107 M | -110 M | -110 M | -110 M | -110 M | - | -102 M | -102 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 122 M | -110 M | 20.2 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
1.06 B | $ 2.56 | 1.24 % | $ 1.35 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
-609 M | $ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.62 | 0.62 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.14 | -2.13 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 1.22 | 27.44 % | $ 28.5 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 12.66 | -1.59 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.83 | -9.94 % | $ 3.58 M | USA |